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Introduction
Maintenance of an intact barrier is the paramount function of the continuous endothelium (as opposed to fenestrated and sinusoidal endothelia) lining a variety of different organs such as the brain, the skin, skeletal muscle and the lung (Pries & Kuebler, 2006) . In particular, this function is of vital physiological relevance in the pulmonary microcirculation, which is thereby more restrictive to transendothelial water and protein flux as compared to, for example, endothelial cells of the larger pulmonary blood vessels (Parker & Yoshikawa, 2002) . This is pivotal as the lung endothelial (and epithelial) barrier warrants efficient gas exchange by preventing interstitial (and alveolar) oedema formation. As a result of its constitutively tight vascular barrier, the pulmonary microcirculation has concomitantly developed into a preferential site of active transcytosis, warranting constant active transcellular exchange between the vascular and interstitial compartment while passive paracellular fluxes are kept to a minimum (Armstrong et al. 2012) . That notwithstanding, a considerable range of mediators, toxins and pathogens, reviewed previously in detail Uhlig et al. 2014) , impair lung vascular barrier function. While this response may have presented an evolutionary advantage at some stage (in that it allows the washing out or dilution of invading pathogens or toxins in aquatic or semi-aquatic lifeforms, and permits influx of soluble immune mediators and recruitment of innate immune cells), the resulting oedema formation and subsequent respiratory failure pose a lethal threat to mammalian species. Considerable research effort has therefore focused on a better understanding of the molecular mechanisms that cause, prevent, or reverse lung endothelial barrier failure. From this research, several novel strategies have emerged over the past years which show considerable promise for preservation or reconstitution of endothelial barrier function in vitro and in preclinical trials. While an exhaustive list of mechanisms regulating endothelial barrier function and their potential pharmacological utilization is beyond the scope of this review, we will focus specifically on a few selected hot topics with promise for rapid or future testing in clinical trials. These comprise the regulatory role of sphingolipids and sphingolipid-signalling modifying agents, the role of endothelial ion channels with an emphasis on transient-receptor potential (TRP) channels, the effects of angiopoietins and their synthetic mimics, and endothelial barrier regulation by prostaglandins. In addition, we will preface this review with physiological considerations of the role and regulation of endothelial transcytosis in lung endothelial barrier function, and the relevance of interendothelial communication via gap junctional molecules.
Endothelial transcytosis
The lung microvascular endothelium is abundant in caveolae, which mediate active transport of selected molecules from the vascular to the interstitial compartment. Endothelial transcytosis has been extensively studied for albumin, which is actively transported into the interstitial space by caveolae following binding to its receptor, gp60, on the apical endothelial surface in pulmonary microvessels (Minshall & Malik, 2006) . Notably, however, neither the molecular structure of gp60, which along with several other albumin-binding proteins was initially identified by antibody-based ligand blotting and crosslinking studies (Schnitzer et al. 1988) , nor the physiological relevance of transendothelial albumin transport in lung microvessels has so far been unveiled.
Caveolae are small, 50-80 nm -shaped invaginations of the plasma membrane (Schnitzer et al. 1988) which are formed by an asymmetrical distribution of glycosphingolipids to the plasma membrane's outer leaflet (Tuma & Hubbard, 2003) and the presence of the eponymous structural proteins caveolin-1 (cav-1), caveolin-2 and caveolin-3, of which the former appears to be the most relevant and, hence, is the most extensively studied (Vogel et al. 1998; Drab et al. 2001; Razani et al. 2002) . Caveolin proteins can undergo a variety of post-translational modifications including palmitoylation and phosphorylation of their serine, threonine and tyrosine residues, most notably phosphorylation of cav-1 at tyrosine 14 by Src kinases (Sverdlov et al. 2007 ). Tyr 14 phosphorylation seems to play important roles in (epithelial) caveolae formation and (endothelial) albumin transcytosis, which are reduced in cells expressing a phosphorylation defective cav-1 mutant where Tyr 14 had been replaced by phenylalanine (Minshall et al. 2003; Orlichenko et al. 2006) . Conversely, endothelial cells expressing a phosphomimicking cav-1 mutant form more and larger vesicles, presumably because cav-1 phosphorylation causes dispersion of negatively charged phosphotyrosine residues and, thus, swelling and subsequent scission of caveolae from the plasma membrane (Zimnicka et al. 2016) . Notably, however, Tyr 14 phosphorylation is prominent in endothelial cells but not in pericytes, fibroblasts or other cells abundant in caveolin-1 (Aoki et al. 1999) . Whether this discrepancy relates to a lower rate of transcytosis in the latter cell types, or reflects cell type-specific differences in caveolar regulation remains unknown. The functional relevance of other post-translational modifications in cav-1 is even less clear. In addition to structural caveolin proteins, caveolae require scaffolding and adapter proteins, which have been termed cavins 1-4 and which regulate caveolin abundance and recruitment presumably via direct protein-protein interaction (Liu & Pilch, 2008; Hansen et al. 2009; Zhu et al. 2017) , thereby determining caveolar morphogenesis and size in a tissue-specific manner (Hansen et al. 2013) .
Caveolar transcytosis involves a series of tightly regulated steps including caveolar budding at and scission from the apical membrane to form transport vesicles (Oh et al. 1998) and subsequent docking and fusion with the basolateral membrane and cargo release. Cargo selection for caveolar transcytosis is likely based on the abundance of receptors localized to caveolar microdomains at the plasma membrane (Mayor et al. 2014) with ligand binding to the receptor triggering endo-and transcytosis (Minshall et al. 2000) . Caveolar budding and scission critically depend upon Src family kinases which phosphorylate caveolins (vide supra) as well as dynamin, a GTPase that is critical for 'pinching off' the caveolar vesicles from the cell membrane (Oh et al. 1998) . Budding and scission also require local actin depolymerization as indicated by the inhibition of caveolar endocytosis by cytochalasin D (Pelkmans et al. 2002) .
While transcytosis across the lung endothelium was long considered to occur at a constant rate, recent studies indicate that caveolar transcytosis is tightly regulated. As such, increased transendothelial albumin transport has been reported following inflammatory (Hu et al. 2008) , hormonal , or pharmacological stimulation (Hu et al. 2006) . Notably, thrombin, the prototypic stimulus of paracellular gap formation in endothelial cells in vitro, markedly increases albumin transcytosis across lung microvascular (but not macrovascular) endothelial cells both in vitro and in situ ). This effect is mediated via activation of acid sphingomyelinase (ASM), a lysosomal enzyme that hydrolyses sphingomyelin into ceramide (Fig. 1 ). ASM and ceramide had previously been implicated in endocytotic events, in that membrane injury causes rapid exocytosis of lysosomes, and subsequent ASM-dependent S. Simmons and others J Physiol 597.4 endocytosis of the membrane lesion, suggesting a critical role for ceramide in vesicle budding and/or scission (Tam et al. 2010) . In case of albumin transcytosis, this response is mediated via an ASM-and (presumably) ceramide-dependent increase in de novo synthesis of cav-1 which is paralleled by enhanced cav-1 recruitment to caveolae, resulting in a marked increase in overall cav-1 content in membrane lipid raft domains that promotes formation, budding, and scission of caveolae . The recognition of ASM-dependent stimulated albumin transcytosis across the pulmonary endothelium opens up several new avenues for consideration in that it (a) challenges the classic view of total protein or albumin content in the bronchoalveolar lavage (BAL) as a marker of paracellular leak in inflammatory lung disorders, (b) poses a potential window for targeted drug delivery to the pulmonary endo-and epithelium, and (c) may provide for an intriguing hypothetical explanation for the pulmonary phenotype in Farber disease, a deficiency in acid ceramidase which results in accumulation of ceramide in lung tissue and a striking accumulation of proteins including albumin, IgG and IgM in the alveolar space (Yu et al. 2018) . It should, however, be duly noted that at present the in vivo relevance of endothelial transcytosis versus paracellular permeability for quantitative protein leak in the injured lung remains speculative.
Gap junctional communication
Gap junctions are formed by the interaction of two hemichannels (named connexons) on adjacent cells to create an intercellular communication pathway. Each connexon is composed of six connexins in a homo-or heteromeric (identical/different connexins per connexon) and homoor heterotypic (identical/different connexons per gap junction) arrangement. The pulmonary endothelium expresses three different types of connexins (Cx) named according to their molecular mass, namely Cx37, Cx40 and Cx43 (Bhattacharya et al. 2011) . Notably, and in striking contrast to systemic vascular beds, which only express Cx40 in arterioles, Cx40 is also abundantly expressed in the endothelium of alveolar capillaries in the lung (Tallini et al. 2007; Wang et al. 2012) . A series of studies have recently implicated connexins in lung vascular barrier failure, suggesting a critical role for interendothelial crosstalk in the regulation of lung endothelial permeability. Cx43 mediates the spread of locally evoked endothelial Ca 2+ signals and subsequent inflammatory responses along the pulmonary endothelium (Parthasarathi et al. 2006) . Conversely, inhibition of Cx43 gap junctional communication prevents endothelial leakage in response to local acid injury at sites 700 μm distant from the site of acid instillation (Parthasarathi, 2012) . Notably, inhibition of endothelial Cx43 also blocked endothelial permeability at the actual injury site, suggesting that Cx43 may regulate barrier function by intracellular effects independent of intercellular signal conduction (Parthasarathi, 2012) . In line with this notion, inhibition of Cx37 and Cx43 by the mimetic peptide 37, 43 Gap27 reduced blood-brain barrier permeability in a model of intravenous bradykinin infusion (De Bock et al. 2011) and inhibition of Cx43 prevented the increase in the lung microvascular filtration coefficient in response to thrombin infusion (Parthasarathi et al. 2006) . Importantly, the latter two findings cannot be attributed to intercellular propagation of a permeability signal via gap junctional communication, since both stimuli (bradykinin and thrombin, respectively) had been administered systemically, i.e. acted directly on all endothelial cells without the requirement for a conducted response. Similarly, Cx43 knockdown or non-specific inhibition of connexins by carbenoxolone attenuated the endothelial permeability response to thrombin and lipopolysaccharide (LPS) in vitro (O'Donnell et al. 2014) . The mechanism by which connexins regulate endothelial permeability directly at the site of stimulation or injury, i.e. seemingly independent of their role in intercellular communication and conducted responses, remains enigmatic. In cerebral microvascular endothelial cells, both Cx43 and Cx40 colocalize and coprecipitate with several tight junction proteins including occludin, claudin-5 and ZO-1 (Nagasawa et al. 2006) . Cx43 has also been proposed to regulate the activity of extracellular signal-regulated kinases (ERKs)/mitogen-activated protein kinases (MAPKs) and Src in a gap junction-independent manner, as activation of these kinases by bisphosphonates in bone cells plated at such low density as to exclude formation of intercellular gap-junctional channels can be blocked by connexon inhibitors and is absent in cells derived from cx43-knockout mice (Plotkin et al. 2002) . It has been proposed that this effect may be attributable to transient opening of connexon hemichannels causing a conformational change in Cx43, possibly leading to activation of Src and downstream kinases such as ERK/MAPK (Goodenough & Paul, 2003) ; however, this hypothesis still awaits experimental validation, and its implications for endothelial barrier regulation are unclear. Of relevance with respect to the latter, endothelial Cx43 overexpression has also been shown to increase expression of Rock1 and thus phosphorylation of myosin light chain and endothelial permeability while Cx43 silencing had opposite effects . Whether this interaction between Cx43 and the RhoA/Rho kinase pathway relates to its role in the formation of gap junctions is unclear.
In contrast to these findings, however, gap junction blockers caused a loss rather than an enhancement in barrier function in porcine blood-brain barrier and rat lung endothelial cells, respectively (Nagasawa et al. 2006) . Impaired barrier function in lung microvascular endothelial cells in response to LPS also correlates with a concomitant loss of Cx40 (Zhou et al. 2018) . However, whether this association is indicative of a protective role of Cx40 in lung vascular barrier homeostasis, or merely reflects the well-documented loss of Cx40 expression (Rignault et al. 2007 ) and coupling (Tyml, 2011) under inflammatory conditions independent of their effect on vascular permeability remains to be elucidated. It should also be noted that endothelial connexins not only facilitate interendothelial communication, but can form gap junctions with juxtaposed non-endothelial cells including smooth muscle cells (as so called myoendothelial junctions with important roles in the regulation of vascular tone (Straub et al. 2014) ), neutrophils (Zahler et al. 2003) , and -potentially -interstitial fibroblasts or alveolar epithelial cells. However, the extent to which these heterologous cell-cell contacts contribute to the regulation of endothelial barrier function is so far unknown.
Taken together, gap junctions and connexins emerge as important regulators of endothelial permeability, yet their effects seem to be at least dichotomous with remote effects mediated via their classic role in intercellular signal propagation and local effects that likely are independent of intercellular communication but involve intracellular protein interactions of connexins that are as of yet surprisingly little understood and characterized.
Sphingolipids
Eukaryotic cell membranes are composed of phospholipids such as phophatidylcholine, phophatidylethanolamine and sphingomyelin, which provide the supporting matrix for signal transduction processes. Among the phospholipids the minor population of sphingolipids is of particular importance in routing intra-and extracellular stimuli as bioactive signal transducers that control fundamental cellular functions such as proliferation, migration, apoptosis and senescence (Olivera & Spiegel, 1993; Venable et al. 1995; Lee et al. 1998 Lee et al. , 1999 Kolesnick & Fuks, 2003) .
Structurally common among all sphingolipids is a sphingoid base that in the case of ceramide is associated by an amide bond to a fatty acid chain. Ceramide is an intermediate of the sequential decomposition and hydrolysis of sphingomyelin by the sphingomyelinase pathway, or is de novo synthesized by the action of ceramide synthases (CerS). Ceramide is further catabolized by ceramidases to sphingosine, which, in turn, gets phosphorylated by sphingosine kinase-1 or -2 (SPHK-1 or -2) to form sphingosine-1-phosphate (S1P). S1P gets degraded in most tissues by the S1P lyase, which cleaves S1P to 2-hexadecenal and phophoethanolamine, or by the S1P phosphatase-1 and -2, and the lipid phosphate phosphatase-3 through dephosphorylation to sphingosine.
Ceramide
All sphingolipid species and their respective catalytic enzymes have been described in the lung, but evidence has been provided that long-chain ceramide species, i.e. ceramides with 16-or 24-carbon fatty acid chains, are rather abundant (ß70%) and correlate with a relative increase of CerS2 and CerS5 compared to other CerS in the lung tissue (Xu et al. 2005; Petrache et al. 2013) . Changes in the long-chain ceramide homeostasis by ablation of CerS2, which catalyses the de novo ceramide synthesis, caused a shift from 24-to 16-carbon fatty acid chain ceramides, which, in turn, resulted in perivascular inflammation and oedema formation (Petrache et al. 2013) . The importance of ceramide for the regulation of vascular permeability and the pathogenesis of both acute and chronic lung injury has been demonstrated in the context of platelet-activating factor (PAF)-induced lung oedema (Goggel et al. 2004) . While it has been demonstrated that ASM deficiency protects against LPS-induced endothelial apoptosis by the arrest of ceramide synthesis (Haimovitz-Friedman et al. 1997) , the endothelial response to PAF could be linked to ASM-dependent ceramide production (Goggel et al. 2004) . Notably, PAF-induced endothelial ceramide elevation results not in apoptosis but increased vascular permeability ( Fig. 2) (Goggel et al. 2004) . Interestingly, ceramides with long saturated acyl chains, and analogous diglycerides, efficiently displace cholesterol from lipid rafts, and contribute to composition of caveolae by recruitment of the polymodal cation channel transient receptor potential canonical 6 (TRPC6), the specific caveolar structural protein cav-1 and endothelial nitric oxide (NO) synthase (eNOS; Goggel et al. 2004; Megha & London, 2004; Kuebler et al. 2010; Yang et al. 2010) . Subsequent Ca 2+ influx via TRPC6 cation channels triggers endothelial barrier failure which is further amplified by concomitant silencing of eNOS via its interaction with cav-1. The latter effect is attributable to basal NO production acting as an endogenous break on caveolar TRPC6 channels in a cGMP-(and presumably, protein kinase G-) dependent manner (Samapati et al. 2012) .
Of relevance in the context of lung oedema and injury, ceramides have been shown not only to increase vascular permeability, but also to weaken alveolar integrity by antagonizing the surface tension lowering capacities of natural surfactant ( Fig. 2) (Ryan et al. 2003) . Alveolar ceramides increase upon tumour necrosis factor-α (TNF-α) stimulation, and, consecutively, alter surfactant and epithelial permeability ( Fig. 2) (Ryan et al. 2003) . Increasingly, ceramides also receive attention as pro-apoptotic second messengers which can induce J Physiol 597.4 endothelial cell apoptosis and oxidative stress, and, in consequence, amplify lung injury (Petrache et al. 2005) . As such, intratracheal short-chain (C 12 ) ceramide instillation causes apoptosis in type II alveolar epithelial cells and, predominantly, in endothelial cells (Petrache et al. 2005) , which goes along with the observation that cigarette-smoke-induced emphysema patients exhibit elevated ceramide levels and changes in ceramide species profiles (Petrache et al. 2005) . These results support a central role of lung endothelial cell apoptosis in the development of emphysema and implicate ceramide as an important mediator of endothelial cell apoptosis. The latter notion is in line with previous studies which identified ceramide as critical for the induction of apoptosis in pulmonary endothelial cells by LPS (Haimovitz-Friedman et al. 1997) . Importantly, and further complicating matters, a growing body of evidence suggests that specific ceramide molecular species may have disparate biological functions and reflect distinct pathophysiological processes, as highlighted by the fact that the ratio of C 24 /C 16 ceramides in blood may serve as a biomarker of metabolic and cardiovascular diseases, i.e. coronary heart disease risk and heart-failure risk (Peterson et al. 2018 ).
Induction of endothelial apoptosis and subsequent changes in endothelial barrier function are not a unique feature of ceramide signalling. For example, sepsis-induced pulmonary microvascular dysfunction as a result of an inducible NO synthase (iNOS)/ NADPH oxidase-dependent signalling cascade causes caspase-dependent apoptosis of pulmonary microvascular endothelial cells and subsequent barrier failure (Gill et al. 2014 (Gill et al. , 2015 Wang et al. 2017) . As such, endothelial apoptosis presents an important mechanism for increased endothelial permeability.
Sphingosine-1-phosphate
Destabilization of the lung epithelial barrier can not only be induced by ceramide but has also been demonstrated to be caused by the absence of the sphingolipid S1P (Sammani et al. 2010) . S1P binds five heterotrimeric G-protein-coupled receptors, i.e. S1PR1-5, which exhibit high affinities to S1P in nanomolar concentrations, and are distributed on multiple cell lineages, e.g. hematopoietic, fibroblastic cells, endothelial and epithelial cells (Rosen & Goetzl, 2005) . Genetic deletion of S1PR2 or knockdown of S1PR3 led to improved protection against LPS-induced epithelial barrier disruption (Sammani et al. 2010) . To date, endothelial cells and red blood cells have been identified as major cellular sources for S1P. Intracellular S1P is exported by specific transporters into the circulatory fluids (in roughly micromolar concentrations), i.e. blood and lymph, as well as into abluminal compartments (in roughly nanomolar concentrations). In the lung, the major source of S1P is endothelial cells that export S1P via the endothelium-specific S1P secretory molecule spinster-homolog-2 (SPNS2) (Fukuhara et al. 2012) . However, also platelets release S1P (Spns2-independently) and may contribute locally to improve endothelial barrier function as observed in high endothelial venules (HEVs), specialized postcapillary venules that facilitate lymphocyte immigration from the blood vasculature to lymph nodes (Herzog et al. 2013) . This observation and the basal pulmonary drainage in mice that display reduced levels of S1P, e.g. pS1Pless and Sphk-1-deficient mice (Li et al. 2008; Camerer et al. 2009 ), pinpoint to the importance of S1P in regulating endothelial barrier function and, thereby, counteracting the disruptive potential of its progenitor ceramide (Fig. 2) .
The majority (ß60%) of S1P in the plasma is bound to high-density lipoproteins (HDL), while ß30% of S1P are associated with albumin, and ß10% is carried by other lipoproteins (Christoffersen et al. 2011) . The main plasma carrier of S1P in the HDL fraction is the chaperone apolipoprotein M (ApoM) (Christoffersen et al. 2006) . The abundance of ApoM-associated S1P in plasma accounts for signalling of S1PR1 on endothelial cells which results in improved vascular barrier function through the stimulation of adherens junction formation ( Fig. 2 ; Kumaraswamy et al. 2012) . Therefore, conditional deletion of S1PR1 in endothelial cells led to increased vascular permeability (Gaengel et al. 2012) . Endothelial cell-specific deletion of S1PR1 causes a dramatic increase in pulmonary vascular permeability while ApoM −/− KO mice showed a mild but significant leakage phenotype, which could be rescued with S1PR1 agonists (Blaho et al. 2015) . The non-specific S1PR-antagonist FTY720 (Fingolimod) caused the development of macular oedema in a clinical trial (Cohen et al. 2010) . Moreover, FTY720 binds to S1PR1, which drives receptor poly-ubiquitinylation upon internalization, and subsequent degradation (Oo et al. 2011) . Consequentially, a massive increase in pulmonary permeability was observed following FTY720 stimulation if S1PR1 internalization was not prevented (Oo et al. 2011) .
How endothelial barrier integrity is controlled by the S1P-S1PR axis and which molecular mechanisms regulate vascular permeability in the steady state and under pathological conditions are still points of consideration. It has been shown, that the dynamic control of cytoskeletal remodelling plays a central role in endothelial barrier integrity. The S1P-S1PR signalling axis has been demonstrated to support intercellular junctions and cell-matrix adherence, and facilitates actin remodelling in vitro (Garcia et al. 2001) . Here, endothelial barrier enhancement has been induced by S1P through S1PR1 and S1PR3 G iα signalling, and could be linked to Racand Rho-dependent cytoskeletal rearrangement in vitro (Garcia et al. 2001; Schaphorst et al. 2003) . In this context, it appears that Rac-dependent translocation of the cortactin-actin-related protein 2/3 complex (Arp2/3), an F-actin binding protein, to the lamellipodia region induces actin polymerization upon S1P stimulation of endothelial cells in vitro (Dudek et al. 2004; Lee et al. 2006; Belvitch et al. 2017) . Furthermore, the non-muscle myosin light chain kinase isoform (nmMLCK) gets phosphorylated resulting in increased cell-cell adhesion and, therefore, barrier enhancement (Dudek et al. 2010) . Interestingly, a recent study demonstrated that MYLK coding polymorphisms, which are related to acute respiratory distress syndrome (ARDS) and acute lung injury (ALI), result in reduced levels of S1P-induced phosphorylation of nmMLCK, and, consequently, loss of barrier integrity . Recently, simvastatin, a member of the anti-inflammatory and vascular-protective HMG-CoA reductase inhibitors, has been described as upregulating S1PR1 transcription and expression by activating the transcription factor KLF2 in vitro and in vivo (Sun et al. 2017) . KLF2 is a transcription factor activated by mechanosensing and controls a majority of gene expression programs under shear stress (Parmar et al. 2006 ) that contribute critically to endothelial barrier integrity (Kuebler, 2017) . Interestingly, Klf2-and S1PR1-deficient mice exhibit comparable vascular defects (Kuo et al. 1997; Liu et al. 2000) , supporting the notion that S1PR1 may act downstream of Klf2 in barrier maintenance.
Taken together, the barrier-protective action of S1P is mediated through S1PR1. However, in the S1PR3 promoter region two single nucleotide polymorphisms were identified that are associated with reduced risks of acute respiratory distress syndrome during sepsis (Sun et al. 2013) . Although S1PR1 is most abundantly expressed in endothelial cells, S1PR2 and S1PR3 are also expressed to a lesser extent (Wilkerson & Argraves, 2014) and may become upregulated under pathological conditions such as pneumonia (Gutbier et al. 2018b) . In contrast to S1PR1, S1PR2 and S1PR3 can negatively affect alveolar and endothelial barrier function, which efficiently could be antagonized by blockade of S1PR2 and S1PR3 signalling Peng et al. 2004; Sammani et al. 2010; Cui et al. 2013; Zhang et al. 2013) . The potential clinical importance of the barrier-disruptive effect of S1PR3 agonism is underlined by the correlation of increased S1PR3 release in endothelial cell microparticles with the mortality of patients with ARDS (Sun et al. 2012) .
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Lysophosphatidic acid
The extracellular hydrolysis of lysophosphatidylcholine (LPC), catalysed by the lysophosphodiesterase autotaxin (ATX), produces the lysophospholipid lysophosphatidic acid (LPA) (Okudaira et al. 2010; Moolenaar & Perrakis, 2011) . Intracellularly, LPA synthesis is mediated by phospholipase D and phosphatic acid-specific phospholipase A, or, alternatively, by acylglycerol kinase (Eder et al. 2000; Bektas et al. 2005) . LPA is important for processes in vivo as diverse as proliferation, migration, cytokine/chemokine secretion, platelet aggregation, smooth muscle cell (SMC) contraction and neurite retraction (Schumacher et al. 1979; Tigyi et al. 1994 Tigyi et al. , 1996 Toews et al. 1997; Stahle et al. 2003; Cummings et al. 2004) . LPA binds to at least six distinct G-protein-coupled receptors (LPAR1-6) and, therefore, activates multiple downstream targets in a wide range of cell types including airway epithelial cells. Lung epithelial cells have been shown to sense exogenous LPA predominantly through LPAR1-3 receptors which results in cytokine release (Cummings et al. 2004; Saatian et al. 2006; Zhao et al. 2011b) . Human BAL fluids show significant LPA levels in the steady state which further increase upon allergen challenge, while in preclinical models of bleomycin-induced lung fibrosis, LPS-induced ALI, as well as Th2-mediated asthma disease severity, correlates with increased LPA concentrations in BAL fluids (Georas et al. 2007; Tager et al. 2008; Zhao et al. 2009 Zhao et al. , 2011a . However, increased LPA formation does not necessarily seem to mediate these disease processes, but may at least in part present a counter-regulatory mechanism, as LPA in the airways was found to stabilize lung epithelial barrier integrity through protein kinase C (PKC) δ-and ζ-mediated E-cadherin accumulation at cell-cell junctions (Zhao et al. 2007; He et al. 2009 ). Along similar lines, efficient repair of alveolar epithelial cells in ALI is essential in order to maintain a functional epithelial barrier. ATX is capable of activating intracellular cytoskeleton-related proteins, i.e. PKCδ or cortactin, through generation of extracellular LPA, which induces cytoskeleton rearrangements and results in directed epithelial cell migration (Zhao et al. 2011a) . In endothelial monolayers, LPA has been reported to stabilize barrier function and to reduce permeability in vitro ( Fig. 2 ; Alexander et al. 1998; English et al. 1999) . Recently, the influence of LPA on lung endothelial barrier function has been investigated with the LPAR1 antagonist AM966, an anti-fibrotic agent, in vitro (Cai et al. 2017) . Treatment of human lung microvascular endothelial cells (HLMVECs) with AM966 caused activation of RhoA/Rho kinase, subsequent phosphorylation of the myosin light chain, and increased vascular permeability in vitro (Cai et al. 2017) , suggesting a barrier-protective role of endothelial LPAR1 signalling (Fig. 2) . Analogous to S1P signalling, however, the effects of LPA on lung barrier function seem to be more complex. Impairment of LPAR1 signalling has been shown to attenuate LPS-induced acute inflammation albeit it did not result in changes in lung protein extravasation (Zhao et al. 2011b) . Lung vascular barrier deterioration as a function of LPAR1 signalling is, however, evident in LPAR1-deficient mice, which are less susceptible to fibrosis upon bleomycin exposure and show reduced fibroblast recruitment and diminished oedema formation (Tager et al. 2008) . These contradictory results indicate that the action of LPA is likely tissue dependent, since LPA is able to reduce the blood-brain barrier in vivo Yu et al. 2014) , while it affects lymphocyte extravasation across HEVs in peripheral lymph nodes and HEV endothelial cells, which express both LPAR1 and LPAR4 and show strong morphological changes in response to exogenous LPA (Nakasaki et al. 2008) . Inhibition of ATX impaired the lymphocyte extravasation from HEVs in vivo, inducing lymphocyte accumulation within the endothelial cells and the subendothelial cell compartment, revealing the importance of the ATX-LPA-LPAR1/4 signalling axis for lymphocyte homing across the HEV endothelial cell barrier Bai et al. 2013 ). Yet, even for agonists of the same receptor (LPAR1) in the same microvascular bed (i.e. the lung), results seem to vary from barrier-protective to -disruptive effects. Confounding effects of different models and experimental conditions apart, this effect may hint at a potential biased agonism of this G-protein-coupled receptor.
An alternative explanation for the differential actions of LPA may be derived from the above outlined studies on ceramide or S1P. In plasma, the total LPA pool is composed of distinct species featuring esterified fatty acid chains with diverse structural modifications that each activate different LPARs (Bandoh et al. 2000) . Petrache et al. (2013) have described that an abnormal ceramide species balance is sufficient to increase lung inflammation and trigger tissue remodelling. Therefore, it would be worthwhile profiling LPA species in experimental models of lung diseases with reduced barrier integrity. Furthermore, as a carrier protein of LPA, serum albumin has been identified in Xenopus oocytes, but a detailed analysis of LPA binding proteins in plasma or lung tissues of mouse or men remains to be performed (Tigyi et al. 1991; Tigyi & Miledi, 1992) . Given that chaperone-dependent receptor activation has already received attention in the case of ApoM-bound S1P (Christoffersen et al. 2006) , a screening of LPA carrier protein associations in certain lung pathologies deserves consideration. To receive new insights into specific LPA-dependent lung pathologies, both approaches may help in order to uncover potential molecular acceptors for pharmacological interventions.
Transient receptor potential channels
The transient receptor potential (TRP) channel superfamily is a family of non-selective cation channels that contribute relevantly to Ca 2+ influx and signalling in the lung endothelium (Pedersen et al. 2005) . The TRP family is subdivided into seven subfamilies based on amino acid homology: TRPC (classical or canonical), TRPV (vanilloid), TRPM (melastatin), TRPML (mucolipin), TRPP (polycystin), TRPA (ankyrin) and TRPN (NO-mechano potential C); the latter is found only in invertebrates and fish (Nilius & Owsianik, 2011) . Uniquely for ion channels that usually show little differences in the permeability coefficient for specific ions among family members (Voets et al. 2004) , the TRP superfamily show a significant range in permeability for monovalent (Na + and K + ) and multivalent (Ca 2+ ) cations. While TRPM4 and TRPM5 are impermeable to Ca 2+ but transport Na + and K + selectively (Launay et al. 2002; Hofmann et al. 2003) , the permeability ratios for Ca 2+ over Na + (P Ca /P Na ) ranges from 0.3 for TRPM2 to >100 for TRPV5 and TRPV6 (Pedersen et al. 2005) . While TRP channels play important roles in Ca 2+ influx into cells, it is important to keep in mind that not all TRP-dependent Ca 2+ influx will actually go through TRP channels. Rather, local influx of Ca 2+ and other cations via TRP channels may depolarize cells, causing subsequent bulk Ca 2+ inflow via voltage-gated Ca 2+ channels (Samapati et al. 2012 ). Influx of Ca 2+ has been identified as a key trigger for increases in endothelial paracellular permeability through cytoskeletal reorganization, myosin light chain kinase activation, and inhibition of cAMP generation (Uhlig et al. 2014) . Based on this perception, TRP channels have gained attention as promising new therapeutic targets in diseases associated with impaired lung endothelial barrier function, such as ARDS. TRPC, TRPV, TRPM and TRPP are the TRP channels that are predominantly expressed in lung endothelial cells. Each mature channel consists of four subunits, of which each contains six transmembrane domains that exist in either combination as homotetramer or heterotetramer (Goldenberg et al. 2015) . Among the lung endothelium-expressed TRP channels TRPC1/4, TRPC6, TRPV4 and TRPM2 have received special recognition for the promotion of vascular permeability in certain pathologies, specifically ALI/ARDS and lung oedema.
TRPC
The TRPC family consists of seven members, of which TRPC2 is a pseudogene in humans. TRPC1-7 share an invariant amino acid sequence (EWKFAR) in the C-terminus, also referred to as TRP box, as well as three to four NH 2 -terminal ankyrin-like domains (Pedersen et al. 2005; Villalta & Townsley, 2013) . TRPC1 is most closely related to TRPC4 and TRPC5, while TRPC3 groups with TRPC6 and TRPC7 (Dietrich & Gudermann, 2014) . Primary endothelial cells cultured from human pulmonary artery or mouse lung express TRPC1, TRPC3, TRPC4, TRPC5 and TRPC6 (Tiruppathi et al. 2002; Paria et al. 2004; Weissmann et al. 2012) , whereas human pulmonary artery endothelial cells express TRPC1, TRPC4 and TRPC6 in vitro (Schwingshackl, 2016) . Furthermore, TRPC1, TRPC3, TRPC4, TRPC6 and TRPC7 have been identified in rat pulmonary vascular endothelium of intact lungs in situ (Alvarez et al. 2005) . TRPCs may function as store-operated channels activated by depletion of endoplasmic reticulum (ER) Ca 2+ stores, as shown for the activation of TRPC1/4. Alternatively, TRPC3/6/7 function as receptor-operated channels that can be activated by diacylglycerol (DAG) through G-protein-or tyrosine kinase-dependent signalling pathways (Gudermann et al. 2004; Villalta & Townsley, 2013) . Activation of TRPC channels in lung endothelium characteristically results in Ca 2+ influx and subsequent vascular barrier failure and endothelial contraction (Uhlig et al. 2014) . For example, activation by PAF causes rapid recruitment of TRPC6 channels into caveolae of lung endothelial cells (vide supra), which will facilitate endothelial Ca 2+ influx and increases endothelial permeability ( Fig. 3 ; Samapati et al. 2012) . In lung ischaemia-reperfusion-induced oedema, the initial step in the pathogenesis of injury is an increase in reactive oxygen species (ROS) and intracellular Ca 2+ concentration (Fig. 3) , which subsequently cause changes in cell morphology and increased endothelial leakage, followed by extravasation of plasma, macromolecules and immune cells (Weissmann et al. 2012) . In line with a critical role for Ca 2+ entry via TRPC6 as a mechanism of lung vascular leak, mice deficient in TRPC6 are protected against ischaemia-reperfusion-induced oedema, as shown by stable lung weights and capillary filtration coefficient (K fc ) values before and after ischaemia-reperfusion (Weissmann et al. 2012) .
TRPV
Beside the TRPC family of ion channels, the TRPV family with its six members presents a subject of intense research in respiratory health and disease. TRPV1 channels have attracted interest as therapeutic targets in asthma and cough (Lee & Gu, 2009) , and TRPV2 plays a critical role in Ca 2+ entry in alveolar type II cells (Fois et al. 2012 ). Reduced expression of TRPV5 and TRPV6 has been found in human tumour tissues from non-small cell lung cancer patients, which appears to be associated with decreased median survival after surgical resection (Lehen'kyi et al. 2012; Fan et al. 2014 ). To our knowledge, no function in the lung or airways has been described for TRPV3 as of yet. Currently, TRPV4 is the most extensively studied channel J Physiol 597.4 of this family and has been proven to play a key role in lung endothelial barrier regulation (Morty & Kuebler, 2014) . In the lung, TRPV4 has been identified in vascular SMCs (Yang et al. 2006) , endothelial cells (Earley et al. 2005) and epithelial cells of the alveolae (Alvarez et al. 2006) , trachea (Arniges et al. 2004 ) and bronchi (Fernandez-Fernandez et al. 2008) . Additionally, TRPV4 is highly expressed in leukocytes, i.e. macrophages and neutrophils, which reside in the lung and facilitate immediate host defence and coordinate inflammatory responses through the release of, for example, cytokines, chemokines and ROS (Damann et al. 2009; Hamanaka et al. 2010; Goldenberg et al. 2015) . Like other TRPV channels, TRPV4 is thermosensitive and becomes activated in a temperature range from 24°C to 38°C. TRPV4 also serves as a mechanosensor, as it is activated by membrane stretch, shear stress and viscous loading (Goldenberg et al. 2015) . The relevance of TRPV4's mechanosensing properties has been demonstrated in isolated mouse lungs, in that mechanical stretch resulted in TRPV4-mediated endothelial Ca 2+ influx barrier failure (Hamanaka et al. 2007; Yin et al. 2008; Michalick et al. 2017) . High peak inspiratory pressure activates TRPV4 via formation of the arachidonic acid metabolite epoxyeicosatrienoic acid, a potent stimulator of TRPV4 (Vriens et al. 2005; Zheng et al. 2013) , with a subsequent increase in pulmonary vascular permeability (Hamanaka et al. 2007) . Similarly, circumferential endothelial stretch secondary to hydrostatic stress induces Ca 2+ influx via TRPV4 into endothelial cells (Jian et al. 2008 ) and increases lung vascular permeability by a Ca 2+ -dependent activation of the myosin light chain kinase ( Fig. 3 ; Yin et al. 2008) . In line with these findings on stretch-induced TRPV4 activation and barrier failure in isolated-perfused lung models, genetic deficiency or pharmacological inhibition of TRPV4 by HC-067047 was recently shown to attenuate endothelial Ca 2+ responses to lung overdistention and to protect mice from overventilation-induced vascular leakage and lung injury (Michalick et al. 2017) . In this study, the activation of TRPV4 was mediated through phosphorylation at its serine 824 residue by serum/glucocorticoid-regulated kinase 1 (Michalick et al. 2017) . The role of neutrophilic TRPV4 in endothelial barrier failure, in contrast, seems to be modest, as demonstrated in a murine model of ALI using bone marrow chimeric mice. Here, Trpv4-deficient mice were protected from ALI induced by acid instillation independent of haematopoietic reconstitution with wild-type bone marrow. These results suggest that the barrier disruptive role of TRPV4 relates to its expression on endothelial cells rather than neutrophils (Yin et al. 2016) . TRPV4 has also been described as being involved in oxidative stress-induced endothelial barrier failure in that H 2 O 2 exposure induces Ca 2+ influx through TRPV4 in mouse and human lung microvascular endothelial cells in a Fyn-dependent (a Src family kinase) manner, again resulting in increased endothelial permeability (Suresh et al. 2015) .
TRPM
TRPMs are a group of oxidant-activated cation channels that form the melastatin family of TRP cation channels. The TRPM subfamily consists of eight members that can be divided into four groups based on their phylogenetic analysis, TRPM1/3, TRPM6/7, TRPM4/5 and TRPM2/8, of which TRPM2 is highly express in endothelial cells. TRPM2 is a cation channel that mediates Ca 2+ entry in response to intracellular ADP-ribose (ADPR) that is generated during oxidative stress. The key feature of TRPM2 is a consensus region for pyrophosphatases, also referred to as the Nudix box, which has not been found in other TRPM channels (Dietrich & Gudermann, 2014) . Binding of ADPR in this region triggers TRPM2 activation (Fig. 3) (Dietrich et al. 2017) . ROS are important mediators of endothelial barrier dysfunction in pathologies such as ARDS, ischaemia-reperfusion and hyperoxia (Christofidou-Solomidou & Muzykantov, 2006) and promote interendothelial gap formation at least in part by stimulating Ca 2+ entry into endothelial cells to (Cioffi, 2011) . In human pulmonary artery endothelial cells, H 2 O 2 at non-cytolytic concentrations stimulates Ca 2+ influx via TRPM2 channels, resulting in an increase in endothelial permeability ( Fig. 3 ; Hecquet et al. 2008) . Importantly, the oxidant-dependent activation of TRPM2 in endothelial cells may play a key role in the dialogue between endothelial cells and polymorphonuclear neutrophils (PMNs) (Mittal et al. 2017 ). In order to be able to transmigrate to sites of inflammation and infection, PMNs induce the disassembly of actin filaments in endothelial cells and the formation of interendothelial gaps (Meegan et al. 2017) . Conditional deletion of TRPM2 in endothelial cells of Trpm2 iEC mice reduces transmigration and sequestration of PMNs in tissue upon LPS challenge, indicating a prominent role of TRPM2 in the regulation of endothelial permeability for transmigrating immune cells. As a result, deletion of TRPM2 in endothelial cells increases the survival of mice in response to a lethal dose of LPS in comparison to wild-type controls (Mittal et al. 2017) . In line with the activation of TRPM2 by ADPR, knockdown of the poly-ADPR polymerase enzyme (PARP-1), which is responsible for the generation of ADPR, replicates the transmigration defect of PMNs (Mittal et al. 2017) . Therefore, TRPM2 channels in endothelial cells actively regulate endothelial barrier integrity by facilitating Ca 2+ influx to endothelial cells and by promoting the transmigration of PMNs across endothelial cells.
CFTR
Cystic fibrosis transmembrane conductance regulator (CFTR) is a member of the ATP-binding cassette (ABC) transporter family that regulate anion transport, particularly across epithelial cells . However, CFTR is expressed in numerous tissues and cells, including lung endothelial cells (Tousson et al. 1998) . The pathological function of this channel has been primarily studied in the context of cystic fibrosis, a disease caused by genetic mutations in the CFTR gene that cause impaired chloride and bicarbonate transport via CFTR, and, therefore, cause a pathological osmotic drive for water transit in and out of the cells (Rubin, 2018) . However, recent work suggests that CFTR is not functionally limited to the regulation of cellular osmosis but that it also contributes to the control of endothelial barrier function (Brown et al. 2014) . In this study, the CFTR antagonists CFTR inh -172 and GlyH-101 were shown to increase permeability in human and rat pulmonary endothelial cells in a dose-dependent manner. This finding may be of clinical relevance, as oedema has been described as a presenting symptom in cystic fibrosis disease, yet this has so far largely been attributed to hypoproteinaemia (Fleisher et al. 1964; Gunn et al. 1978) . Along similar lines, a recent study in a porcine volume overload model of pulmonary oedema demonstrated reduced oedema formation following treatment with the CFTR potentiator ivacaftor . While the authors attributed this outcome primarily to improved alveolar fluid clearance via CFTR, CFTR-dependent endothelial barrier stabilization may have equally contributed to the protective effect of ivacaftor.
The exact mechanisms by which CFTR inhibition causes endothelial leak remain to be elucidated. Loss of tight intercellular contacts, redistribution of junctional β-catenin, and scattered actin stress fibre formation have been proposed as mechanisms by which CFTR inhibition leads endothelial barrier integrity to deteriorate (Brown et al. 2014 ). As discussed above, intracellular S1P has been shown to control the cellular localization of VE-cadherin and β-catenin and, thereupon, promotes barrier stabilization in human pulmonary artery endothelial cells ( Fig. 3 ; Usatyuk et al. 2011) . Notably, CFTR has been implicated in the uptake of S1P in pulmonary endothelial cells and vascular smooth muscle cells; however, whether reduced S1P uptake contributes to lung endothelial barrier loss following inhibition of CFTR channels remains unclear Brown et al. 2014) .
NKCC
The Na cotransporters mediate a net influx of ions into cells because of the inwardly directed chemical gradients for Na + and Cl − ions (Hamann et al. 2010) . NKCC cotransporters couple the electroneutral cellular uptake of one Na + and K + with two Cl − across the cell membrane (Hamann et al. 2010) . NKCC has two isoforms, NKCC1 and NKCC2, which share 60% identity. NKCC2 (Slc12a1) is almost exclusively expressed in the kidney, where it is found in the cells of the thick ascending limb of the loop of Henle (Gamba & Friedman, 2009 ). On the other hand, NKCC1 (Slc12a2) is ubiquitously expressed in tissue including the lung endothelial cells (Haas & Forbush, 1998) . A contribution of NKCC1 to endothelial barrier regulation has been reported in a rat ischaemic-stroke model (O'Donnell et al. 2004) . In this study, bumetanide treatment inhibited NKCC1 function at the blood-brain barrier and thus reduced cerebral oedema formation during ischaemia (O'Donnell et al. 2004 ). Several models have demonstrated either pro-oedematous effects of upregulated NKCC1 expression, e.g. following leptospirosis infection (Andrade et al. 2007 ), or, conversely, attenuated oedema formation following NKCC1 inhibition by furosemide or bumetanide (Solymosi et al. 2013) . While these effects have largely been attributed to NKCC1 expression in alveolar epithelial cells, the role of NKCC1 in lung endothelial barrier regulation has been largely disregarded as of yet. Notably, LPS exposure in mice causes less vascular permeability in mice lacking NKCC1 as compared to their corresponding wild-type mice as determined by extravasation of Evans Blue dye and lung wet-to-dry weight ratio (Nguyen et al. 2007) . In this study, the authors proposed that NKCC1 may regulate endothelial barrier function via changes in cell volume and cell shape ( Fig. 3 ; Nguyen et al. 2007) . While the relevance and mechanism of NKCC1-dependent lung endothelial barrier regulation remain to be clarified, its implication for lung oedema formation would provide an intriguing explanation for the rapid effects of NKCC1 inhibitors in lung oedema, which frequently precedes any increase in urinary output.
In conclusion, a growing set of endothelial ion channels have emerged as important regulators of endothelial barrier integrity. Activation of TRP channels mediates endothelial barrier disruption in a range of inflammatory or injurious conditions, and some of these ion channels have recently become targeted for clinical trials in lung oedema, e.g. TRPV4 for the treatment of pulmonary oedema in cardiac failure (NCT02135861). On the other hand, intact CFTR channels seem to strengthen endothelial barrier function. In contrast, the role of ion transporters such as NKCC1 in lung endothelial barrier regulation has so far been little explored, and their relevance in this context remains to be clarified. At a general level, much more needs to be learned about the individual roles of the various ion channels discussed, and their up-and downstream pathways. Over and above that, we must not treat individual channels as solitary factors, but consider that different channels will functionally and, possibly, structurally interact with each other, either via changing electrochemical gradients, or -in some cases -via direct protein-protein interactions.
Prostaglandins
Prostaglandins (PGs) are synthetized by many tissues and cells, including vascular endothelial cells. Upon hydrolysis of plasma membrane phospholipids by phospholipase A2, and subsequent intracellular release of arachidonic acid (AA), cyclooxygenase 1 and 2 (COX-1/2) convert AA into the intermediate prostanoids PGG 2 and PGH 2 (Samuelsson et al. 1978; Smith et al. 2000) . Next, several synthases process these intermediates into specific PGs, i.e. PGE 2 , PGD 2 , PGF 2α , thromboxane (TxA2), or prostacyclin (PGI 2 ). Alternatively, dehydration within the cyclopentane ring of PGE 2 and PGD 2 causes the generation of PGA 2 and PGJ 2 (Claar et al. 2015; Yagami et al. 2016) . PGE 2 activates four PG-specific receptors, EP1-4, that signal individually through the G-proteins G q (EP1), G s (EP2/EP4) and G i (EP3), while PGI 2 activates the prostacyclin receptor IP (Smith et al. 2000; Claar et al. 2015; Yagami et al. 2016) .
The influence of PGs on vascular permeability has been described as being context dependent and sometimes contradictory. Barrier protective effects have been demonstrated for PGE 2 and PGI 2 upon binding to EP4 or the IP receptor in both vascular endothelium studies in vitro and ventilator-induced lung injury models in vivo (Birukova et al. 2015; Claar et al. 2015; Yagami et al. 2016) . PGE 2 release by epithelial cells exerts a barrier-stabilizing effect on endothelial cells in vitro, highlighting the importance of epithelial-endothelial crosstalk in the regulation of vascular permeability and the maintenance of an intact endothelial barrier (Barnthaler et al. 2017) .
Recent studies further revealed a potent barrierprotective effect of PGA 2 when sensed by the EP4 receptor on epithelial cells in vitro and in animal models of lung injury. Interestingly, PGD 2 , PGF 2α and PGJ 2 show no or only modest effects on endothelial cell permeability Ohmura et al. 2017) . PGE 2 and PGI 2 promote endothelial stability through activation of protein kinase A, cAMP-activated guanine nucleotide exchange factor Epac1 and the GTPase Rac1 (Fukuhara et al. 2005; Birukova et al. 2007) . PGI 2 (t 1/2 : 6-8 min) had a less potent effect on barrier integrity as compared to PGE 2 (t 1/2 : 8-11 min) while the stable PGI 2 analogue iloprost (ILO, t 1/2 : 30-40 min) was more effective in supporting barrier integrity, suggesting that the relatively short half-life of PGI 2 may present a limiting factor for its protective action (Birukova et al. 2009 ).
In addition to PGE 2 and PGI 2 , oxidized phospholipids such as oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC) promote vascular barrier function in vitro and in vivo (Fig. 4) . OxPAPC exerted a sustained barrier-enhancing effect mediated by EP4 in an LPS-induced lung injury model, suggesting a novel role for EP4 in permeability regulation (Oskolkova et al. , 2018 . Based on the barrier-protective effect of OxPAPC, a new phospholipase-resistant phosphatidyl choline attached to ILO (ILO-PC) was synthesized and subsequently investigated regarding its effect on endothelial cell permeability. ILO-PC caused sustained endothelial cell permeability enhancement in cells and animal models compared to free ILO, revealing higher potency and longer effect. In endothelial cells, prolonged retention of ILO-PC was observed, suggesting an increased interaction of ILO-PC intracellularly and/or extracellularly (Oskolkova et al. 2018) . The latter study illustrates that despite the diverse and complex physiological and pathophysiological effects of PGs in the lung, a rising number of potent synthetic PG analogues provide opportunities for novel therapeutic strategies to target specific PG-triggered pathways.
Angiopoietin
In addition to the barrier-enhancing effect of some bioactive lipid mediators, such as PGs, angiopoietins, i.e. angiopoietin (Ang)-1 and -2, have been recognized as important regulators of vascular barrier integrity. Ang-1 and Ang-2 are peptide ligands that bind the Tie-2 receptor, predominantly expressed on endothelial cells (Davis et al. 1996; Maisonpierre et al. 1997) . Ang-1 is expressed in vascular SMCs and phosphorylates Tie-2, while Ang-2 antagonizes Ang-1 and, thereby, prevents Tie-2 activation and increased vascular leakage (Suri et al. 1996; Thurston, 2003; Roviezzo et al. 2005; Parikh et al. 2006) . Ang-2, which is expressed and stored in intracellular vesicles in endothelial cells, is elevated in serum of patients with sepsis-associated lung injury, supporting a role for Ang-2 as biomarker in ARDS (Parikh et al. 2006) . In line with this notion, a recent in vitro study demonstrated an association of LPS-induced endothelial hyper-permeability with Ang-2 release (Janga et al. 2018) .
In addition to its direct role on endothelial barrier function, the Ang/Tie-2 signalling axis has recently been identified as a central regulator of microvascular thrombus formation in septic patients, as abrogation of Tie-2 signalling results in disseminated intravascular coagulation and marks early pathogenesis in sepsis . Receptor-agonist interactions and potential therapeutic implications for the improvement of endothelial barrier integrity Physiological prostaglandins PGE 2 , PGA 2 and PGI 2 and angiopoietin-1 as well as synthetic agonists OxPAPC, ILO, ILO-PC and vasculotide increase endothelial barrier integrity. MSCs produce and secrete both Ang-1 and PGE 2 , but also release barrier promoting miRNA by EVs. Ang, angiopoietin; EP4, prostaglandin receptor 4; ILO, iloprost; ILO-PC, phosphatidyl choline attached to iloprost; IP, prostacyclin receptor; miRNA, micro RNA; MSC, mesenchymal stem cell; MSC-EV, mesenchymal stem cell-derived extracellular vesicles; OxPAPC, oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine; PGA 2 , prostaglandin A 2 ; PGE 2 , prostaglandin E 2 ; PGI 2 , prostaglandin I 2 /prostacyclin; Tie-2, angiopoietin receptor-2.
J Physiol 597.4 (Higgins et al. 2018) . In septic patients, increased Ang-2 levels were also found to correlate with reduced levels of microRNA-150 (miR-150). miR-150 plays important roles in endothelial differentiation and vasculogenesis (Luo et al. 2013) , and miR-150 −/− mice have a vascular leakage phenotype that can be rescued by administration of a miR-150 mimic. Notably, the miR-150 mimic also reduced Ang-2 production, thus identifying miR-150 as a novel Ang-2 suppressor, and an enhancer of vascular integrity (Rajput et al. 2016) .
In contrast to the association between injurious stimuli and Ang-2 levels, murine pneumonia-induced lung injury models show reduced levels of circulating Ang-1, while therapeutic administration of exogenous Ang-1 reduces vascular permeability, indicating an important homeostatic role and therapeutic perspective of Ang-1 in lung injury in pneumonia (Gutbier et al. 2018a) . The trigger for the imbalance in the expression and activation of Ang-1 and Ang-2 remains to be characterized, since it could not be attributed to Toll-like receptor activation in vitro, suggesting that other stimuli promote the differential expression of both Ang-1 and Ang-2 (Hilbert et al. 2017) .
Based on the barrier-enhancing effect of Ang-1 via Tie-2 phosphorylation, Tie-2 agonists are considered to have promising potential for novel therapeutic approaches for endothelial barrier stabilization in acute lung injury (David et al. 2011) . Of particular interest as a Tie-2 agonist is vasculotide, a synthetic peptide clustered with polyethelene glycol (Fig. 4) . In a series of studies, a Tie-2-dependent increase in vascular barrier function by vasculotide has recently been demonstrated in several murine lung injury models (David et al. 2011; Sugiyama et al. 2015; Gutbier et al. 2017; Trieu et al. 2018) , suggesting that vasculotide could be a promising strategy for endothelial barrier enhancement in clinical scenarios of ARDS and lung oedema.
The mechanisms underlying the homeostasis of the Ang1-and Ang2-dependent Tie-2 signalling are not fully understood. Even less is known about Ang1-activated Tie-1 signalling, another known receptor for Ang-1, and its role in endothelial barrier regulation. Additionally, the implications of a putative Tie-1/Tie-2 crosstalk on endothelial and epithelial cells for ALI/ARDS have not been completely addressed (Saharinen et al. 2005) . Nevertheless, there are promising approaches for targeted Ang-2 suppression by miRNAs, and encouraging attempts have been made for the therapeutic exploitation of the barrier-stabilizing effect of Ang-1 through the development of Ang-1-specific mimetics. Moreover, with the help of targeted gene editing through the CRISPR-Cas9 system, which was recently reported to successfully target the Ang-Tie-2 system in primary endothelial cells, new approaches for the investigation of endothelial permeability will arise (Gong et al. 2017) .
Extracellular vesicles
Extracellular vesicles (EVs) are small phospholipid-based particles, containing proteins, lipids, RNAs or DNAs, which promote intercellular and even interorgan communication (Araldi et al. 2012; Aucamp et al. 2016) . To date, three groups of EVs have been classified based on their size and mechanism of formation: microvesicles (MVs; 100 nm to 1 μm), apoptotic bodies (1-4 μm) and exosomes (40-100 nm). While MVs are generated by shedding or outward budding of the plasma membrane, exosomes are produced within cells through inward budding and released from multivesicular bodies (Araldi et al. 2012; Nana-Sinkam et al. 2017) . Vascular endothelial cells and epithelial cells release EVs upon exogenous stimulation with LPS, hypoxia, pollutants or microbial pathogens (Nana-Sinkam et al. 2017) . As of late, EVs have received increasing attention in the pathogenesis and propagation of lung diseases. Notably, in murine in vivo models, ventilator-induced lung injury (VILI) is associated with an increased release of endotheliumderived EVs (Cabrera-Benitez et al. 2015) , which may contribute to the pathophysiology of VILI as EVs can attenuate NO release from cultured endothelial cells by decreasing eNOS phosphorylation and hsp90 association consistent with the notion of EV-induced endothelial dysfunction (Essayagh et al. 2005; Densmore et al. 2006) .
The correlation between EV release and the severity of ALI/ARDS directed attention to EV contents (McVey et al. 2012) . These investigations revealed that post-transcriptional gene silencing can be mediated through intercellular EV exchange. Specifically miRNAs, such as miR-146a and miR-155, are detectable in EVs, and regulate mechanisms of ALI (Cai et al. 2012; Zeng et al. 2013) . Transfer of miRNAs among cells via EVs has been shown for endothelial cells, bronchial epithelial cells and mesenchymal stem cells (MSCs) and, in fact, has been associated with ALI or ARDS (Fujita et al. 2015; Monsel et al. 2015; Aliotta et al. 2016) . Furthermore, several biolipid mediators such as TxA 2 , phospholipids and sphingolipids have been implicated in the regulation of barrier integrity and are, notably, also directly or indirectly linked to the formation and function of MVs (Goggel et al. 2004; Maniatis et al. 2008) .
Lately, MSCs and their therapeutic potential in ALI/ARDS have received emerging interest (Walter et al. 2014) . Despite their well-documented protective effects in a large range of different animal models of ALI (Lee et al. 2011 ), MSCs do not engraft permanently into injured lungs (Kotton et al. 2005) . Instead, MSCs seem to confer their protective effect by release of soluble mediators, as their protective effect can be replicated by treatment with cell-free conditioned medium from MSCs ). Along these lines, several studies have shown that MSC-derived MVs restore barrier function and prevent pulmonary oedema formation by facilitating lung tissue repair (Zhu et al. 2014; Monsel et al. 2015; Matthay et al. 2017) . This recognition opens up new therapeutic options with the potential of a 'cell-free cell therapy' by MSC-derived MVs for the treatment of ALI/ARDS. One explanation for the barrier-enhancing effect of EVs can be attributed to an increased VE-cadherin expression and enhanced VE-cadherin and β-catenin interaction, supporting barrier integrity (Menge et al. 2013; Potter et al. 2018) . Notably, BAL fluid from MSC-EV treated mice show enhanced levels of keratinocyte growth factor (KGF) and PGE 2 , supporting the idea of a barrier-promoting effect of MSC-EVs via direct delivery either of these soluble factors or of genetic material encoding for their increased formation (Stone et al. 2017) . Lung-resident MSCs also secrete PGE 2 and suppress the effector function of the adaptive immunity in the lung (Jarvinen et al. 2008) . It is therefore tempting to speculate whether MSCs via PGE 2 may -in addition to exerting barrier-protective effects (Fig. 4) -facilitate an anti-inflammatory response through a change of the effector function of lung macrophages. Knockdown of KGF and Ang-1 mRNA in MSC-EVs prevented the protective effect of MSC-EV administration, suggesting important roles for KGF and Ang-1 in lung injury repair mediated by mRNA shuttling through MSC-MVs (Zhu et al. 2014; Monsel et al. 2015; Tang et al. 2017) .
Taken together, EVs serve as intercellular communication shuttles with the potential to regulate vascular permeability in ALI/ARDS with both barrier-disruptive and barrier-protective effects. While the emerging role of EVs makes the understanding of the regulation of lung barrier maintenance, failure and reconstitution even more complex, it also opens new possibilities for therapeutic interventions. Suitable techniques for the isolation as well as the specific characterization of EVs are still challenges for targeted clinical applications. However, recent advances in flow cytometry-based isolation protocols of EVs are promising approaches in order to quantify disease-specific EV profiles that may serve as clinical biomarkers for diagnosis, prognosis, or responsiveness to therapy in lung diseases (McVey et al. 2016) . Therefore, EVs and especially MSC-EVs may provide therapeutic potential for ALI or ARDS in the future, if methodological improvements allow targeted modifications that lead to the development of 'designer EVs' .
Regulation of endothelial barrier function in the lung remains an area of vibrant research as it addresses a highly relevant unmet clinical need, i.e. the maintenance of barrier integrity in acute and chronic disease conditions that are not limited to scenarios of permeability-type lung oedema, but include other acute and chronic lung diseases associated with increased vascular permeability including cardiogenic lung oedema, pulmonary hypertension and interstitial lung disease. Advances in our insights in, for example, the role and mode of action of specific sphingolipid species in defined pathologies have promoted our understanding of the regulation of endothelial barrier integrity, yet still await successful translation and implementation into meaningful clinical strategies. In parallel, new and still poorly understood mechanisms such as the formation and effects of EVs emerge and challenge our perception of the complex and multimodal control of endothelial integrity. New cellular players such as platelets have received increasing attention for their non-haemostatic influence on barrier integrity and immunological effector functions (for a detailed overview on the functions of platelets in ALI and ARDS refer to Middleton et al. 2018) . Beside the bone marrow, the lung has recently been described as a haematopoietic organ that contributes significantly to the systemic platelet pool (Lefrancais et al. 2017) . However, whether platelets released from lung megakaryocytes are functionally different from bone marrow-derived platelets and whether the lung-derived platelet pool has a specific influence on barrier integrity and/or facilitates certain immune reactions in the lung are points of future investigation. Finally, and of particular clinical interest, research into TRP channels has raised considerable enthusiasm because of the possible therapeutic potential for TRP channel antagonists in the prevention or treatment of lung endothelial barrier failure; yet, despite a large body of promising preclinical data, results from clinical studies are still outstanding in this field. agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.
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